| [1] |
Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5):594-599.
|
| [2] |
唐陈伟，童焕军，汤朝晖. 肝内胆管癌的综合治疗[J]. 中国普通外科杂志, 2019, 28(8):903-909.
|
| [3] |
吴锦洪，周冬儿，于源泉, 等. 肝内胆管癌新辅助化疗后手术切除1例报告并文献复习[J]. 中国实用外科杂志, 2017, 37(7)：818-820, 822.
|
| [4] |
Le VH, O'Connor VV, Li D, et al. Outcomes of neoadjuvant therapy for cholangiocarcinoma: a review of existing evidence assessing treatment response and R0 resection rate[J]. J Surg Oncol, 2021, 123(1):164-171.
|
| [5] |
Fruscione M, Pickens RC, Baker EH, et al. Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: a systematic review[J]. Curr Probl Cancer, 2021, 45(1):100614.
|
| [6] |
Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105(7):839-847.
|
| [7] |
Rho YS, Barrera I, Metrakos P, et al. Complete resolution of metastatic gallbladder cancer after standard gemcitabine-cisplatin combination therapy[J]. Cureus, 2015, 7(12):e415.
|
| [8] |
Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery[J]. Ann Surg Oncol, 2015, 22 Suppl 3:S1093-1099.
|
| [9] |
Adachi K, Okuwaki K, Nishiyama R, et al. A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin[J]. Clin J Gastroenterol, 2019, 12(5):466-472.
|
| [10] |
Imafuji H, Matsuo Y, Aoyama Y, et al. A case of unresectable hilar cholangiocarcinoma resected curatively through effective response to neoadjuvant chemotherapy[J]. Gan To Kagaku Ryoho, 2020, 47(8): 1268-1270.
|
| [11] |
Tatsuguchi T, Gotoh K, Kobayashi S, et al. Pathologic complete response after gemcitabine and S-1 chemotherapy for far advanced intrahepatic cholangiocarcinoma[J]. Int Cancer Conf J, 2018, 7(3): 93-97.
|
| [12] |
Babu VPK, Talwar V, Raina S, et al. Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: a study from North India Cancer Centre[J]. Indian J Cancer, 2018, 55(3): 222-225.
|
| [13] |
Zaccari P, Cardinale V, Severi C, et al. Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas[J]. World J Gastroenterol, 2019, 25(31):4343-4359.
|
| [14] |
Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(12):1707-1712.
|
| [15] |
Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6):824-830.
|
| [16] |
Miura JT, Johnston FM, Tsai S, et al. Chemotherapy for surgically resected intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(11):3716-3723．
|
| [17] |
Ma KW, Cheung TT, Leung B, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis[J]. Medicine, 2019, 98(5): e14013.
|
| [18] |
胡春秀，余维，魏启春. 肝内胆管细胞癌根治术后辅助化疗的价值[J]. 实用肿瘤杂志, 2020, 35(2):140-144.
|
| [19] |
董志涛，沈伟峰. 肝内胆管细胞癌的治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2020, 9(1)：6-10.
|
| [20] |
Mou H, Yu L, Liao Q, et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report[J]. BMC Cancer, 2018, 18(1):1105.
|
| [21] |
Sui M, Li Y, Wang H, et al. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade[J].J Immunother Cancer, 2019, 7(1):125.
|